Age
N/A
Organization/Year
USPSTF/2002
Recommended Frequency
N/A
Comments/Grade
USPSTF recommends against routine use of tamoxifen or raloxifene for primary prevention of breast cancer inwomen at low or average risk for breast cancer. (D)
USPSTF recommends that clinicians dscuss chemoprevention with women at high risk for breast cancer and low risk of adverse effects of chemoprevention. Clinicians should inform patientsof potential benefits and harms of chemoprevention. (B)
